DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20171096

A prospective randomized study: role of enalapril on oxidative stress in newly diagnosed type 2 diabetes mellitus and its correlation with glycaemic status

Sathiya Vinotha A. T., Ranjani R.

Abstract


Background: Oxidative stress is demonstrated the pathological conditions such as Atherosclerosis and diabetes mellitus. It has been suggested to be involved in the pathogenesis of both macro and microvascular complications. This study was designed to evaluate the effect of Enalapril on oxidative stress markers in type 2 diabetic patients.

Methods: A Prospective Randomized controlled study was conducted in 75 participants in which 25 healthy volunteers and 50 newly diagnosed DM2 patients who were divided into three groups of 25 in each. In Group II DM2 patients were treated with Metformin alone, in group III DM2 patients were treated with Enalapril and Metformin and 25 healthy volunteers were included in Group I (controls). Oxidative stress parameters, FBS, HbA1c were measured at the time of diagnosis and at 4,8,12 weeks.

Results: There was a significant decrease in free radical production (p<0.05) and significant increase in antioxidant enzymes (p<0.001) in both the patient Groups and positive correlation between oxidative stress markers and FBS and HbA1c (p<0.01).

Conclusions: Oxidative stress measured as LPO is strictly influenced by glycaemic control. Enalapril and Metformin combination in diabetic patients has more significant effect on decreasing the oxidative stress than Metformin alone.


Keywords


ACE inhibitors, Biguanides, Glycated haemoglobin, Reactive oxygen species

Full Text:

PDF

References


Asif M. The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. J Educ Health Promot. 2014;3:1.

Gerald IS, Morino K, Petersen KF, Sono S, Choi CS, Varman TS et al. Regulation of mitochondrial biogenesis by lipoprotein lipase in muscle of insulin-resistant offspring of parents with type 2 diabetes. Diabetes. 2012;61(4):877-87.

William IS, Yorek MA. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal. 2010;12(4):537-57.

Lu H, Koshkin V, Allister EM, Gyulkhandanyan AV, Wheeler MB. Molecular and metabolic evidence for mitochondrial defects associated with beta-cell dysfunction in a mouse model of type 2 diabetes. Diabetes. 2010;59(2):448-59.

Rury RH, Sanjoy KP, Angelyn Bethel M, Matthews DR, Andrew H, Neil W et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.

Alqahtani N, Waseem Abdul GK, Mohamed HA, Yasar Albushra AR. Use of glycated hemoglobin in the diagnosis of diabetes mellitus and pre-diabetes and role of fasting plasma glucose, oral glucose tolerance test. Int J Prev Med. 2013;4(9):1025-102.

Azam M, Marwood L, Ismail K, Evans T, Sivaprasad S, Winkley K et al. Diabetes complications at presentation and one year by glycated haemoglobin at diagnosis in a multiethnic and diverse socioeconomic population: results from the south london diabetes study. J Diabetes Res. 2015;2015:587673.

George MM, Copeland KC. Current treatment options for type 2 diabetes mellitus in youth: today’s realities and lessons from the TODAY. Curr Diabetes Rep. 2013;13(1):72-80.

Aguayo Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5:6.

Bajaj S, Khan A. Antioxidants and diabetes. Indian J Endocrinol Metab. 2012;16(l2):267-71.

Xie Q, Hao CM, Ji L, Hu D, Zhu T, Li X et al. ACEI/ARB underused in patients with type 2 diabetes in chinese population (CCMR-3B Study). PLoS One. 2015;10(2):e011697.

Steven S, Münzel T, Daiber A. Exploiting the pleiotropic antioxidant effects of established drugs in cardiovascular disease. Int J Mol Sci. 2015;16(8):18185-223.

Tavafi M. Diabetic nephropathy and antioxidants. J Nephropathol. 2013;2(1):20-7.

Rao YM, lakshmi IA, Saroja M. Effect of ACE inhibitors on antioxidant status in streptozotocin induced diabetic rats. Asian J Pharmaceu Clin Res. 2011;4(1):134-7.

Zhu A, Romero R, Petty HR. An enzymatic colorimetric assay for glucose-6-phosphate. Anal Biochem. 2011;419(2):266-7.

Alam N, Rafiquzzaman. Review on in-vivo and in-vitro methods evaluation of antioxidant activity. Saudi Pharmaceu J. 2013;21(2):143-52.

Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058-70.

Adarkwah CC, Gandjour A, Akkerman M, Silvia M. Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in the Netherlands-a markov model. Plos one. 2011;6(10):e26139.

Moinuddin G, Mohammed NI, Kulkarni KS, Kulkarni C. Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressure-overload rats. Cardiovasc J Afr. 2013;24(3):58-65.

Yacoub R, Campbell KN. Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renovasc Disease. 2015;8:29-40.

Kanwar YS, Sun L, Xie P, Liu F, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol. 2011;6:395-423.

Ahmad S, Shahab U, Baig MH, Khan MMS, Khan S, Srivastava AK. Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products. PLoS One. 2013;8(9):e72128.

Vlassara H, Uribarri J. Advanced glycation end products (age) and diabetes: cause, effect, or both? Curr Diab Rep. 2014;14(1):453.

Rupprecht A, Brauer AU, Chenko AS, Goyn J, Hilse KE, Irina G et al. Quantification of uncoupling protein 2 reveals its main expression in immune cells and selective up-regulation during T-Cell proliferation. Plos one. 2012;7(8):e41406.